Article

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

2011-03-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5602894d-2804-5983-936d-24412615712f
DOI: 10.1016/s0168-8278(11)60009-3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIESDOI 10.1016/s0168-8278(11)60009-3Read

A review of standard and newer treatment strategies in hepatitis C.Semantic proximity Read

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.Semantic proximity Read

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Semantic proximity Read

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.Semantic proximity Read

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.Semantic proximity Read

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.Semantic proximity Read

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.Semantic proximity Read

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosisSemantic proximity Read

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.Semantic proximity Read